ViiV Healthcare expects to provide long-acting injectable HIV drugs to low- and middle-income countries
- Did Cloud Seeding Unleash a Deluge in Dubai?
- Scientists Identify Gut Bacteria and Metabolites that Lower Diabetes Risk
- OpenAI’s Model Matches Doctors in Assessing Eye Conditions
- UK: A Smoke-Free Generation by Banning Sales to Those Born After 2009
- Deadly Mutation: A New Monkeypox Variant Emerges in the DRC
- EPA Announces First-Ever Regulation for “Forever Chemicals” in Drinking Water
ViiV Healthcare expects to provide long-acting injectable HIV drugs to low- and middle-income countries
- Red Yeast Rice Scare Grips Japan: Over 114 Hospitalized and 5 Deaths
- Long COVID Brain Fog: Blood-Brain Barrier Damage and Persistent Inflammation
- FDA has mandated a top-level black box warning for all marketed CAR-T therapies
- Can people with high blood pressure eat peanuts?
- What is the difference between dopamine and dobutamine?
- How long can the patient live after heart stent surgery?
ViiV Healthcare (GSK) expects to provide long-acting injectable HIV drugs to low- and middle-income countries
As early as 2019, the Joint United Nations Programme on AIDS set a lofty goal to end the transmission of HIV by 2030 .
But according to the World Health Organization (WHO) , the current rate of decline in infection rates is not fast enough to achieve that goal.
ViiV Healthcare , owned by GlaxoSmithKline (GSK) , believes it can help change that.
ViiV announced on Friday (May 27) that it is collaborating with the United Nations-backed drug over the patent rights for its long-acting injectable HIV drug cabotegravir for pre-exposure prophylaxis (PrEP) in low- and middle-income countries. Negotiated with the Patent Pool (MPP) .
The deal builds on an existing partnership with MPP that has given more than 20 million people access to a generic version of ViiV’s other HIV drug, dolutegravir , marketed as Dovato .
“Expanding access to this type of injectable medicine is complex and requires all stakeholders to play their part,” Chief Executive Deborah Waterhouse said in a release.
The company noted that the production of long-acting injectables is more complex than oral antiretroviral drugs and also requires capital investment.
But ViiV said it was committed to getting cabotegravir into the market and hoped to reach a licensing deal in the coming months.
ViiV says its cabotegravir injection ( Apretude ) is the first long-acting PrEP injection that reduces the risk of HIV infection and can be given by doctors every other month .
The current list price for a dose is $3,700 , according to GoodRx .
The drug was approved in the US in December and ViiV has submitted it to regulators in Australia, Botswana, Brazil, Kenya, Malawi, South Africa, Uganda and Zimbabwe.
Last year, ViiV won approval from Janssen , a division of Johnson & Johnson, to market cabotegravir and rilpivirine as a long-acting HIV treatment under the marketing name Cabenuva . Just last month, ViiV celebrated the drug’s one-year anniversary with a new label extension, allowing some patients to receive only six treatments a year, every two months.
Gilead Sciences ‘ long-acting drug , lenacapavir , followed, with the FDA submitting a CRL in March about the drug’s compatibility with the proposed vial container CMC. This therapy is administered every six months for multidrug-resistant HIV patients.
MPP’s mission is to “increase access to, and facilitate development of, life-saving medicines in low- and middle-income countries through innovative approaches to voluntary licensing and patent sharing”.
Earlier this month, the National Institutes of Health (NIH) said it would license 11 new coronavirus research tools to MPP, as well as early-stage vaccine and diagnostic candidates.
References:
ViiV Healthcare expects to provide long-acting injectable HIV drugs to low- and middle-income countries
(source:internet, reference only)
Disclaimer of medicaltrend.org
Important Note: The information provided is for informational purposes only and should not be considered as medical advice.
